Current status of experimental therapeutics for prostate cancer

Chulso Moon; Jong Chul Park; Young Kwang Chae; Jin Han Yun; Saechul Kim

doi:10.1016/j.canlet.2008.02.065

Current status of experimental therapeutics for prostate cancer

Chulso Moon, Jong Chul Park, Young Kwang Chae, Jin Han Yun, Saechul Kim

School of Medicine

Research output: Contribution to journal › Article › peer-review

35 Scopus citations

Abstract

Hormone refractory prostate cancer (HRPC) is the progression of disease in the presence of castrate serum levels of testosterone with a median survival of approximately 1 year. A variety of strategies have been developed to improve survival for the patients with advanced prostate cancer. Despite such efforts, the effective treatment modality for those patients has not been established other than chemotherapy. New experimental therapeutics such as gene therapy, vaccine therapy and target therapy use various mechanisms to kill tumor cells selectively while sparing surrounding normal tissues. Furthermore, new approaches in the field of chemoprevention are being made. Recent data from landmark studies, in particular vaccines, have shown improvements in overall survival of HRPC patients.

Original language	English (US)
Pages (from-to)	116-134
Number of pages	19
Journal	Cancer Letters
Volume	266
Issue number	2
DOIs	https://doi.org/10.1016/j.canlet.2008.02.065
State	Published - Aug 8 2008

Keywords

Gene therapy
Hormonal refractory prostate cancer
Immunotherapy
Targeted therapy

ASJC Scopus subject areas

Cancer Research
Molecular Biology
Oncology

Access to Document

10.1016/j.canlet.2008.02.065

Cite this

@article{d1b6115597c9429d92cf4d4468b20e87,

title = "Current status of experimental therapeutics for prostate cancer",

abstract = "Hormone refractory prostate cancer (HRPC) is the progression of disease in the presence of castrate serum levels of testosterone with a median survival of approximately 1 year. A variety of strategies have been developed to improve survival for the patients with advanced prostate cancer. Despite such efforts, the effective treatment modality for those patients has not been established other than chemotherapy. New experimental therapeutics such as gene therapy, vaccine therapy and target therapy use various mechanisms to kill tumor cells selectively while sparing surrounding normal tissues. Furthermore, new approaches in the field of chemoprevention are being made. Recent data from landmark studies, in particular vaccines, have shown improvements in overall survival of HRPC patients.",

keywords = "Gene therapy, Hormonal refractory prostate cancer, Immunotherapy, Targeted therapy",

author = "Chulso Moon and Park, {Jong Chul} and Chae, {Young Kwang} and Yun, {Jin Han} and Saechul Kim",

year = "2008",

month = aug,

day = "8",

doi = "10.1016/j.canlet.2008.02.065",

language = "English (US)",

volume = "266",

pages = "116--134",

journal = "Cancer Letters",

issn = "0304-3835",

publisher = "Elsevier Ireland Ltd",

number = "2",

}

TY - JOUR

T1 - Current status of experimental therapeutics for prostate cancer

AU - Moon, Chulso

AU - Park, Jong Chul

AU - Chae, Young Kwang

AU - Yun, Jin Han

AU - Kim, Saechul

PY - 2008/8/8

Y1 - 2008/8/8

N2 - Hormone refractory prostate cancer (HRPC) is the progression of disease in the presence of castrate serum levels of testosterone with a median survival of approximately 1 year. A variety of strategies have been developed to improve survival for the patients with advanced prostate cancer. Despite such efforts, the effective treatment modality for those patients has not been established other than chemotherapy. New experimental therapeutics such as gene therapy, vaccine therapy and target therapy use various mechanisms to kill tumor cells selectively while sparing surrounding normal tissues. Furthermore, new approaches in the field of chemoprevention are being made. Recent data from landmark studies, in particular vaccines, have shown improvements in overall survival of HRPC patients.

AB - Hormone refractory prostate cancer (HRPC) is the progression of disease in the presence of castrate serum levels of testosterone with a median survival of approximately 1 year. A variety of strategies have been developed to improve survival for the patients with advanced prostate cancer. Despite such efforts, the effective treatment modality for those patients has not been established other than chemotherapy. New experimental therapeutics such as gene therapy, vaccine therapy and target therapy use various mechanisms to kill tumor cells selectively while sparing surrounding normal tissues. Furthermore, new approaches in the field of chemoprevention are being made. Recent data from landmark studies, in particular vaccines, have shown improvements in overall survival of HRPC patients.

KW - Gene therapy

KW - Hormonal refractory prostate cancer

KW - Immunotherapy

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=45049086542&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=45049086542&partnerID=8YFLogxK

U2 - 10.1016/j.canlet.2008.02.065

DO - 10.1016/j.canlet.2008.02.065

M3 - Article

C2 - 18440696

AN - SCOPUS:45049086542

SN - 0304-3835

VL - 266

SP - 116

EP - 134

JO - Cancer Letters

JF - Cancer Letters

IS - 2

ER -

Current status of experimental therapeutics for prostate cancer

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this